New appointment adds clinical expertise to Board
Leeds, 1 June, 2016 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company today announces that it has appointed Professor Shervanthi Homer - Vanniasinkam as a Non- Executive Director with immediate effect.
Professor Homer-Vanniasinkam is a respected Consultant Vascular Surgeon who holds a number of appointments at medical and academic institutions across the country, and is regularly invited to lecture at prestigious establishments across the world. She was recently appointed to the First Chair of Engineering and Surgery at University College London, and currently holds positions which include Clinical Sub - Dean, University of Leeds Medical School and Professor of Surgery University of Warwick Medical School and University Hospitals Coventry and . Professor Homer-Vanniasinkam has been acting as a clinical advisor to the Group for a number of years and has extensive experience of medical research, development and innovation.
John Samuel, Chairman of Tissue Regenix Group commented: "We welcome the appointment of Shervanthi as a Non- Executive Director, having supported Tissue Regenix in an advisory role for a number of years. With a strong commercially - focussed Board we feel it imperative to match this with clinical expertise as the Group continues to grow and bring dCELL® to the market. The appointment of Shervanthi at this time highlights the continued momentum of Tissue Regenix as we expand further into the US marketplace and bring human tissue applications to ."
Full Name: Shervanthi Homer- Vanniasinkam
Other Corporate Board positions: N/A
Consultant Vascular Surgeon, Leeds Vascular Institute, Leeds General Infirmary
Clinical Sub-Dean, University of Leeds Medical School & Director of EXSEL@Leeds
Professor of Surgery (Founding), University of Warwick Medical School &
University Hospitals Coventry and
Professor of Engineering and Surgery, University College London
There is no further information to be disclosed in accordance with the requirements of Schedule Two paragraph (g) of the AIM rules.